Patents Examined by Janet Epps-Smith
  • Patent number: 9839616
    Abstract: The present invention provides a lipid nano-particles, which allow nucleic acids to be easily introduced into cells, comprising a cationic lipid represented by formula (I) (wherein: R1 and R2 are, the same or different, alkenyl, etc, and X3 is absent or is alkyl, etc, X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and Y1 is absent or anion, L1 is a single bond, etc, R3 is alkyl, etc), and the like.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: December 12, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Takeshi Kuboyama, Tomohiro Era, Tomoyuki Naoi
  • Patent number: 9822134
    Abstract: The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: November 21, 2017
    Assignee: SABAG-RFA LTD.
    Inventor: David Segev
  • Patent number: 9814777
    Abstract: The present invention provides targeting lipids of structure L100-linker-L101??(CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: November 14, 2017
    Assignee: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Muthusamy Jayaraman
  • Patent number: 9795668
    Abstract: Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 24, 2017
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Siddhartha Jain, Manmohan Singh, Derek O'Hagan
  • Patent number: 9796749
    Abstract: The invention provides nucleic acid structures of controlled size and shape, comprised of a plurality of oligonucleotides, and methods for their synthesis. The structures are formed, at least in part, by the self-assembly of single stranded oligonucleotides. The location of each oligonucleotide in the resultant structure is known. Accordingly, the structures may be modified with specificity.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: October 24, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Peng Yin, Diming Wei
  • Patent number: 9782337
    Abstract: Compositions comprising one or more compounds expressed by fetal tissues for modulating skin conditions, methods of identifying the compounds, and methods of making and using the compounds are provided.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: October 10, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Chia Soo
  • Patent number: 9775804
    Abstract: The specification relates to an internal structured self assembled liposome (ISSAL), containing a nuclear core molecule or complex including a first affinity enhancing molecule; and a phospholipid-affinity enhancing complex having a phospholipid coupled to second affinity enhancing molecule, wherein the second affinity enhancing molecule couples to the first affinity enhancing molecule. The ISSAL's can be used in, for example and without limitation, the field of drug delivery, vaccination, imaging contrast agents, and nanotechnology, in which liposomes of ordered, self-assembling structure are employed to deliver soluble or insoluble molecules to any sub-cellular address.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: October 3, 2017
    Inventor: Aaron Froese
  • Patent number: 9775931
    Abstract: The invention relates to methods of preparing a bone matrix solution, a bone matrix implant, and variants thereof. The invention also relates to methods of cell culture using the same. The invention further relates to bone matrix scaffolds comprising one or more bone matrix nanofibers, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells and promoting differentiation of stem cells using the same.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: October 3, 2017
    Assignee: LifeNet Health
    Inventors: Michael Francis, Roy Ogle
  • Patent number: 9750243
    Abstract: An aqueous adjuvant concentrate can be prepared using a formulation including: a. from about 15 to about 45% by weight of a potassium salt chosen among di-potassium phosphate, potassium sulfate, potassium nitrate, tri-potassium citrate, potassium salts of ethylenediaminetetraacetic acid and mixture thereof; b. from about 0.5 to about 6% by weight of at least one surfactant and c. from about 3 to about 9% by weight of a hydroxypropyl tamarind gum; wherein a, b, and c are dissolved into the aqueous adjuvant. The aqueous adjuvant can include other compounds such as ah herbicide.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: September 5, 2017
    Assignee: LAMBERTI SPA
    Inventors: Rocco Di Modugno, James Dean Reiss, Bradley Eidem, Valentina Langella, Mauro Riccaboni, Giovanni Floridi, Giuseppe Li Bassi
  • Patent number: 9750257
    Abstract: A coated seed obtained by coating a seed with a coating material containing an inorganic mineral powder and a thermosetting resin powder having an average particle diameter of 10 to 200 ?m, wherein the thermosetting resin powder is a thermosetting resin powder obtained by aggregating a powdery pesticide with a thermosetting resin has an excellent quality.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: September 5, 2017
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Takatoshi Terada, Manabu Tagami, Takashi Sato, Atsushi Iwata, Taro Yokochi, Yasushi Kobayashi
  • Patent number: 9750694
    Abstract: An object of the present invention is to provide a liposome which is excellent in intrapulmonary delivery controllability of drugs or genes and is suited for pulmonary administration. By modifying the surface of a liposome using a terminal hydrophobized polyvinyl alcohol and/or chitosan, retention of drugs or genes encapsulated in the liposome on the surface of lung tissue and transfer of drugs or genes into lung tissue can be properly modulated, and thus in vivo behavior can be controlled.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: September 5, 2017
    Assignees: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hirofumi Takeuchi, Koji Nakano, Hidekazu Toyobuku
  • Patent number: 9744109
    Abstract: The invention relates to active eutectic mixtures of butyl methoxydibenzoylmethane, isopropyl myristate and optionally 12-hydroxystearic acid, personal care products comprising such active eutectic mixtures, a method for preparing such personal care compositions and a method of applying to human skin such personal care compositions.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: August 29, 2017
    Assignee: Conopco. Inc.
    Inventors: Ezat Khoshdel, Stephan Georg Schumm, Yinfang Yao, Qiqing Zhang
  • Patent number: 9738908
    Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification and regulation of gene expression in mammalian cells. The specification describes the design and validation of polynucleotides encoding the Streptococcus pyogenes (S. pyogenes) Cas9 gene and protein and variants of that protein, where the nucleotide sequence has been optimized for expression in mammalian cells, and also modified by fused sequences that enhance various aspects of the CRISPR/Cas system. The specification also describes systems for RNA-guided genome engineering and gene regulation in mammalian cells, including human cells.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: August 22, 2017
    Assignee: System Biosciences, LLC
    Inventor: Fangting Wu
  • Patent number: 9737557
    Abstract: The present invention provides, among other things, a particle which includes a core comprised of self-assembled one or more nucleic acid molecules, the core being characterized by an ability to adopt at least two configurations: a first configuration having a first greatest dimension greater than 2 ?m and; a second configuration having a second greatest dimension less than 500 nm, wherein addition of a film coating converts the core from its first configuration to its second configuration. Methods of making and using of provided particles are also disclosed.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: August 22, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Paula T. Hammond, Jong Bum Lee, Young Hoon Roh
  • Patent number: 9730959
    Abstract: Provided is a biocomposite including cells, a genetic construction, and a scaffold and a method for repairing tissue and organs in mammalians with the biocomposite. The interaction of the components of the biocomposite provides a complex effect on reparative regeneration processes. Also provided is a method for administration of gene-cellular therapeutic constructions to a recipient which can be used in medicine and veterinary to provide reparative processes. After administering the biocomposite to a recipient, the scaffold structure releases the nucleic acids which enter into the cells of a recipient bed and cells of the transplanted product. The nucleic acids are expressed, which results in the increased concentration of a target product responsible for reparative processes.
    Type: Grant
    Filed: December 24, 2012
    Date of Patent: August 15, 2017
    Assignee: “NEXTGEN” COMPANY LIMITED
    Inventors: Artur Aleksandrovich Isaev, Sergej L'vovich Kiselev, Roman Vadimovich Deev, Il'ya Yadigerovich Bozo, Elena Sergeevna Filonenko
  • Patent number: 9730440
    Abstract: There is provided a powder composition comprising a collection of particles (I) having median particle diameter of 10 micrometers to 200 micrometers, wherein each of said particles (I) comprises (a) a covering of a fatty compound having melting point of 50° C. to 110° C. and (b) one or more inner particles (II) comprising one or more complex that contains a cyclopropene compound molecule or a portion of a cyclopropene compound molecule encapsulated in a molecule of a molecular encapsulating agent. Also provided is a slurry comprising water and such a powder. Also provided is a method of contacting plants or plant parts with such a slurry.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: August 15, 2017
    Assignee: Agrofresh Inc.
    Inventors: Yueqian Zhen, Jeffrey A. Coles
  • Patent number: 9732329
    Abstract: The present invention relates generally to a population of cells genetically modified to produce insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells genetically modified to produce insulin in response to physiologically relevant levels of glucose and uses thereof. The cells of the present invention are useful in a wide variety of applications, in particular in the context of therapeutic and prophylactic regimes directed to the treatment of diabetes and/or the amelioration of symptoms associated with diabetes, based on the transplantation of the cells of the present invention into mammals requiring treatment. Also facilitated is the design of in vitro based screening systems for testing the therapeutic effectiveness and/or toxicity of potential adjunctive treatment regimes.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: August 15, 2017
    Assignee: University of Technology, Sydney
    Inventors: Ann Margaret Simpson, Chang Tao
  • Patent number: 9693934
    Abstract: The present invention relates to a cosmetic tissue comprising microemulsion particles, and to a production method for same and method of using same. The present invention provides a cosmetic tissue to which is securely attached a dried composition comprising microemulsion particles of no more than 5,000 nm. Also, the present invention provides a production method for cosmetic tissue comprising: a first step of obtaining a composition comprising microemulsion particles of no more than 5,000 nm; a second step of coating the composition onto a tissue substrate; and a third step of drying the composition, and the present invention provides a method of using same. According to the present invention, after the skin has been cleaned, removal of the remaining water fraction and coating of a dermatological beauty composition are carried out in one go, thereby allowing easy-to-use and effective cosmetic enhancement to the skin.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: July 4, 2017
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Joon Young Hwang, Min Kyung Shim, Young So Kim, Sang Hoon Han
  • Patent number: 9687548
    Abstract: Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 27, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Xin Lu, Sarit S. Agasti, Ronald A. DePinho, Ralph Weissleder
  • Patent number: 9687557
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: June 27, 2017
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz